SCHEMBL4425801

SCHEMBL4425801

COc1ccc(-c2noc(C3CCNCC3)n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.64
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 2/20 0.55
HPGD P15428 1/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
HSD17B10 Q99714 1/20 0.55
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
TLR9 Q9NR96 1/20 0.53
TLR8 Q9NR97 1/20 0.53
TLR7 Q9NYK1 1/20 0.53
MAOA P21397 1/20 0.52
MAOB P27338 1/20 0.52
MAPT P10636 3/20 0.52
TP53 P04637 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
PLAT P00750 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24844952 0.86 NR1H4 (0.61) NR1H4ALDH1A1KDM4EHPGDCASP1
SCHEMBL25433735 0.86 MAPT (0.54) NR1H4ALDH1A1KDM4EHPGDCASP1
SCHEMBL193523 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDCASP1CASP7
SCHEMBL4416033 0.85 NPC1 (0.74) NR1H4ALDH1A1NPC1RAB9ATLR9
SCHEMBL20968160 0.84 NR1H4 (0.69) NR1H4NPC1RAB9ATLR9TLR8
SCHEMBL30506252 0.84 TLR9 (0.70) NR1H4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL20116145 0.84 TLR9 (0.70) NR1H4ALDH1A1KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL412823 0.84 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDCASP1CASP7
Hydrochloric Acid SCHEMBL7551864 0.83 NPC1 (0.72) NR1H4ALDH1A1NPC1RAB9ATLR9
SCHEMBL24844551 0.83 NR1H4 (0.60) NR1H4NPC1RAB9ATLR9TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US claimed
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 US disclosed
CN-119564686-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-03-07 CN disclosed
CN-119523983-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-28 CN disclosed
CN-119424429-A DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2025-02-14 CN disclosed
CN-115003665-B DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) 拜耳公司 2024-11-08 CN disclosed
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-06-04 US disclosed
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 US disclosed
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 US disclosed
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-29 US disclosed
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-11 US disclosed
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-11 US disclosed
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-11 US disclosed
EP-4065574-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2022-10-05 EP disclosed
CN-115003665-A Substituted aminoquinolones as immunoactive DGK alpha inhibitors 拜耳公司 2022-09-02 CN disclosed
WO-2021105117-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 WO disclosed
WO-2021105117-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-06-03 WO disclosed
US-7217714-B1 CCR5 modulators AGOURON PHARMACEUTICALS, INC. (US) 2007-05-15 US disclosed
US-7217714-B1 CCR5 modulators AGOURON PHARMACEUTICALS, INC. (US) 2007-05-15 US disclosed
US-7217714-B1 CCR5 modulators AGOURON PHARMACEUTICALS, INC. (US) 2007-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148194-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION DGKK, DGKG, DGKA NR1H4 1555/4885ALDH1A1 3915/4885KDM4E 1315/4885
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 NR1H4 90/4885ALDH1A1 1059/4885KDM4E 3925/4885
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA NR1H4 1555/4885ALDH1A1 3915/4885KDM4E 1315/4885
US-11998539-B2 Substituted aminoquinolones as DGKalpha inhibitors for immune activation DGKK, DGKG, DGKA NR1H4 1555/4885ALDH1A1 3915/4885KDM4E 1315/4885
US-20230201186-A1 SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION DGKK, DGKG, DGKA NR1H4 1555/4885ALDH1A1 3915/4885KDM4E 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.